Cargando…
Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19
BACKGROUND: After its introduction as standard-of-care for severe COVID-19, dexamethasone has been administered to a large number of patients globally. Detailed knowledge of its impact on the cellular and humoral immune response to SARS-CoV-2 remains scarce. METHODS: We included immunocompetent indi...
Autores principales: | Thibeault, Charlotte, Bardtke, Lara, Vanshylla, Kanika, di Cristanziano, Veronica, Eberhardt, Kirsten A., Stubbemann, Paula, Hillus, David, Tober-Lau, Pinkus, Mukherjee, Parnika, Münn, Friederike, Lippert, Lena J., Helbig, Elisa T., Lingscheid, Tilman, Steinbeis, Fridolin, Mittermaier, Mirja, Witzenrath, Martin, Zoller, Thomas, Klein, Florian, Sander, Leif E., Kurth, Florian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243822/ https://www.ncbi.nlm.nih.gov/pubmed/36881474 http://dx.doi.org/10.1172/jci.insight.166711 |
Ejemplares similares
-
Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage
por: Gruell, Henning, et al.
Publicado: (2022) -
Characterization of antimicrobial use and co-infections among hospitalized patients with COVID-19: a prospective observational cohort study
por: Lingscheid, Tilman, et al.
Publicado: (2022) -
Functional limitations 12 months after SARS-CoV-2 infection correlate with initial disease severity: An observational study of cardiopulmonary exercise capacity testing in COVID-19 convalescents
por: Steinbeis, Fridolin, et al.
Publicado: (2022) -
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
por: Gruell, Henning, et al.
Publicado: (2022) -
Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections
por: Tober-Lau, Pinkus, et al.
Publicado: (2022)